

Market Announcement

5 June 2018

Botanix Pharmaceuticals Limited – Trading Halt

Description

The securities of Botanix Pharmaceuticals Limited (the 'Company') will be placed in trading halt at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Thursday, 7 June 2018 or when the announcement is released to the market.

Security Code:	BOT
----------------	-----

Issued by

Dawn James

Adviser, Listings Compliance (Perth)

5 June 2018

The Manager
Australian Securities Exchange
152-158 St Georges Terrace
PERTH WA 6000

tradinghaltsperth@asx.com.au

Via email

Dear Sir,

REQUEST FOR A TRADING HALT

Pursuant to ASX Listing Rule 17.1, Botanix Pharmaceuticals Limited (ASX: BOT) (**Company**) requests a trading halt of its securities from ASX with effect from commencement of trading on Tuesday 5 June 2018.

In accordance with ASX Listing Rule 17.1, the Company provides the following information regarding this request:

1. The reason for the trading halt is that the Company intends to make an announcement regarding results for its BTX 1204 atopic dermatitis (AD) patient study.
2. The Company requests that the trading halt continue until the earlier of commencement of trading on Thursday 7 June 2018 or when the announcement referred to in paragraph 1 is released to the market.
3. The Company expects the event which will end the trading halt is the announcement referred to in paragraph 1.

The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely



Simon Robertson
Company Secretary